REFERENCES
- Bisno AL, Gerber MA, Gwaltney JM, Kaplan EL, Schwartz RH. Diagnosis and management of group A strepto-coccal pharyngitis: a practice guideline. Infectious Diseases Society of America. Clin Infect Dis 1997; 25: 574–583.
- Jones RN. The impact of antimicrobial resistance: changing epidemiology of community-acquired respiratory tract infections. Am J Health Syst Pharm 1999; 56 Suppl. 3: S4-11.
- Felmingham D, Grüneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191–203.
- Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveil-lance program, 1997-1999. Clin Infect Dis 2001; 32 Suppl. 2: S81-93.
- NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard — Fifth edition. NCCLS document M7-A5 (ISBN 1-56238-394-9). NCCLS: Wayne, PA, USA; 2000.
- NCCLS. Performance standards for antimicrobial suscep-tibility testing. Twelfth informational supplement. NCCLS doc-ument M100-12 (ISBN 1-56238-454-6). NCCLS: Wayne, PA, USA; 2002.
- Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3: 171–196.
- Blondeau JM, Tillotson GS. Antimicrobial susceptibility patterns of respiratory pathogens — a global perspective. Semin Respir Infect 2000; 15: 195–207.
- Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug-resis-tant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917–1924.
- Felmingham D, Washington J. Trends in the antimicro-bial susceptibility of bacterial respiratory tract pathogens — findings of the Alexander Project 1992-1996. J Chemother 1999; 11: 5–21.
- Sahm DF, Jones ME, Hickey ML, Diakun DR, Mani SV, Thornsberry C. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J Antimicrob Chemother 2000; 45: 457–466.
- Barman Balfour JA, Figgitt DP. Telithromycin. Drugs 2001; 61: 815–829.
- Barry AL, Fuchs PC, Brown SD. In vitro activities of the ketolide HMR 3647 against recent Gram-positive clinical isolates and Haemophilus influenzae. Antimicrob Agents Chemother 1998; 42: 2138–2140.
- Pankuch GA, VisaIli MA, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin- and erythromycin-susceptible and - resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998; 42: 624–630.
- Hoban DJ, Zhanel GG, Karlowsky JA. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibi-otics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Diagn Microbiol Infect Dis 1999; 35: 37–44.